Your browser doesn't support javascript.
loading
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Maio, M; Ascierto, P A; Manzyuk, L; Motola-Kuba, D; Penel, N; Cassier, P A; Bariani, G M; De Jesus Acosta, A; Doi, T; Longo, F; Miller, W H; Oh, D-Y; Gottfried, M; Xu, L; Jin, F; Norwood, K; Marabelle, A.
Affiliation
  • Maio M; University of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital, Siena, Italy. Electronic address: maio@unisi.it.
  • Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy.
  • Manzyuk L; Outpatient Medical Treatment Department, NN Blokhin National Medical Research Center of Oncology, Moscow, Russia.
  • Motola-Kuba D; COMOP A.C., Clinical Investigation, Mexico City, Mexico.
  • Penel N; Medical Oncology Department, Centre Oscar Lambret and Lille University, Lille, France.
  • Cassier PA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Bariani GM; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.
  • De Jesus Acosta A; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA.
  • Doi T; Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Longo F; Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, CIBERONC, Madrid, Spain.
  • Miller WH; Segal Cancer Centre, Jewish General Hospital, Montréal, Canada; Department of Medicine, McGill University, Montréal, Canada.
  • Oh DY; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.
  • Gottfried M; Department of Medical Oncology, Meir Medical Center, Kfar Saba, Israel.
  • Xu L; Merck & Co., Inc., Rahway, USA.
  • Jin F; Merck & Co., Inc., Rahway, USA.
  • Norwood K; Merck & Co., Inc., Rahway, USA.
  • Marabelle A; Department of Therapeutic Innovation and Early Trials, Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U1015/CIC1428, Université Paris Saclay, Villejuif, France.
Ann Oncol ; 33(9): 929-938, 2022 09.
Article in En | MEDLINE | ID: mdl-35680043
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: Reino Unido